Esophageal Cancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab and Ramucirumab), and Immunotherapy (Pembrolizumab)), By Disease Indication (Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2019 - 2027

  • Published On : Sep 2019 |
  • Pages : 166 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Esophageal Cancer Drugs Market – Insights

Esophageal cancer drugs are extensively used in the treatment of esophageal adenocarcinoma, squamous cell carcinoma, and others types. More men are affected by esophageal cancer than women. Esophageal cancer is mostly observed in low-income countries. For instance, according to World Cancer Research Fund (WCRF) International report of 2018, highest rate of esophageal cancer was found to be in Malawi, Mongolia, Kenya, and Bangladesh. Treatments such as chemotherapy, immunotherapy, and targeted drug therapies are available for esophageal cancer. Some drugs are used in combinations and are approved by the Food and Drug Administration (FDA) such as XELIRI combinations of Capecitabine and Irinotecan Hydrochloride.

The global esophageal cancer drugs market size was valued at US$ 765.2 million in 2018 and is expected to witness a CAGR of 8.2% over the forecast period (2019 – 2027).

Global Esophageal Cancer Drugs Market Share (%) Analysis, By Therapy Type, 2018

Esophageal Cancer Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing research & development and increasing prevalence of achalasia is expected to drive growth of the esophageal cancer drugs market

Increasing research and development and launches of novel products by key players are major factors that are expected to drive growth of the global esophageal cancer drugs market in the near future. Increasing research and development for new drug discovery for the treatment of esophageal cancer is expected to significantly drive growth of esophageal cancer drugs market size. For instance, in February 2019, researchers at Case Western Reserve University, U.S. found that by blocking two molecular pathways that send signals inside cancer cells could reduce esophageal adenocarcinoma (EAC), the most common esophageal malignancy in the U.S. These findings suggest JNK/TGF-beta-targeted therapy as a new treatment approach to treat esophageal cancer.

Furthermore, the major risk factors that leads to esophageal cancer include age, gender, tobacco, alcohol, Barrett's esophagus, obesity, and achalasia. These factors are expected to increase demand for esophageal cancer drugs over the forecast period. For instance, according to a study published in National Center for Biotechnology Information in 2017, achalasia patients have 50 times higher risk of incidence of esophageal squamous cell carcinoma than the general population. The overall prevalence of achalasia is 9 to 10 in 100,000 people annually, worldwide.

Esophageal Cancer Drugs Market - Restraints

However, high cost of therapy for the treatment of esophageal cancer is expected to restraint the market growth. For instance, as per the report published in Healthday, in 2013, cancer patients paid US$ 207,000 per year for the treatment and medications while in 1995, the cost was US$ 54,100 per year.

Moreover, the side effects caused by esophageal cancer drugs are loss of appetite and weight loss, fatigue, diarrhea, hair loss, sore mouth, hand-foot syndrome, low blood cell counts, blood clots (deep vein thrombosis), nervous system damage, and heart damage. According to the 2017 report of the American Cancer Society (ACS), side effects of esophageal cancer drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel can cause major damage to nerves outside the brain and spinal cord.

Esophageal Cancer Drugs Market - Regional Insights

On the basis of region, the global esophageal cancer drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global esophageal cancer drugs market during the forecast period, owing to high prevalence of esophageal cancer in this region. For instance, the according to American Cancer Society’s report, it projected that around 17,650 new esophageal cancer cases will be diagnosed (13,750 in men and 3,900 in women) in the U.S. by 2019.

Asia Pacific is expected to witness rapid growth in the esophageal cancer drugs market during the forecast period, owing to rise in clinical trials conducted in Asian countries for novel drugs to treat esophageal cancer. For instance, National Cancer Center Hospital, Tokyo started a clinical trial in December 2018, which evaluated the comparative study between combination therapy with induction DCF (docetaxel plus cisplatin and 5-fluorouracil) versus definitive chemo-radiotherapy for locally advanced carcinoma of the thoracic esophagus.

Global Esophageal Cancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Esophageal Cancer Drugs  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2019)

Esophageal Cancer Drugs Market - Competitive Landscape

Key players operating in the global esophageal cancer drugs market include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.

Esophageal cancer occurs in the cells that line the inside of the esophagus. Major symptoms include difficulty in swallowing (dysphagia), unintentional weight loss, chest pain, worsening indigestion or heartburn, coughing or hoarseness. Drugs approved by the Food and Drug Administration (FDA) such as Docetaxel, Trifluridine, and Tipiracil Hydrochloride are extensively used chemotherapy for treatment of esophageal cancer. Immunotherapy drug named Pembrolizumab is also used for the treatment of esophageal cancer. In 2017, FDA granted accelerated approval to pembrolizumab (Keytruda) for patients suffering from recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma.

Market Dynamics

Increasing prevalence of esophageal cancer worldwide is expected to boost esophageal cancer drugs market growth. According to World Cancer Research Fund (WCRF) International 2018, esophageal cancer is the seventh most commonly occurring cancer in men and the 13th most commonly occurring cancer in women. There were over 500,000 new cases in 2018, globally. Moreover, geriatric population is at high risk of developing esophageal cancer and men are more vulnerable to developing esophageal cancer. For instance, according to a data published in American Society of Clinical Oncology (ASCO) in 2018, it is estimated that people between the ages of 45 and 70 have the highest risk of esophageal cancer.

However, no drug therapy has been used to cure esophageal cancer completely and the survival rates of esophageal cancer patient significantly decreases after 5 years of treatment. The esophageal cancer drugs do not have any reliability after 5 years of treatment, which is expected to hamper growth of the esophageal cancer drugs market. For instance, according to the study published in the ASCO in January 2019, the 5-year survival rate of people with esophageal cancer is 19%.

Key features of the study:

  • This report provides in-depth analysis of the esophageal cancer drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2027, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global esophageal cancer drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global esophageal cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts

 Detailed Segmentation:

  • Global Esophageal Cancer Drugs Market, By Therapy Type:
    • Chemotherapy
      • Docetaxel
      • Irinotecan
      • Trifluridine and Tipiracil
      • Carboplatin and Paclitaxel
      • Cisplatin and 5-fluorouracil
      • Cisplatin with Capecitabine
    • Targeted Drug Therapy
      • Trastuzumab
      • Ramucirumab
    • Immunotherapy
      • Pembrolizumab
  • Global Esophageal Cancer Drugs Market, By Disease Indication:
    • Adenocarcinomas
    • Gastrointestinal Stromal Tumors
    • Carcinoid Tumors
    • Squamous Cell Carcinoma
    • Others
  • Global Esophageal Cancer Drugs Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Esophageal Cancer Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Therapy Type:
        • Chemotherapy
          • Docetaxel
          • Irinotecan
          • Trifluridine and Tipiracil
          • Carboplatin and Paclitaxel
          • Cisplatin and 5-fluorouracil
          • Cisplatin with Capecitabine
        • Targeted Drug Therapy
          • Trastuzumab
          • Ramucirumab
        • Immunotherapy
          • Pembrolizumab
      • By Disease Indication:
        • Adenocarcinomas
        • Gastrointestinal Stromal Tumors
        • Carcinoid Tumors
        • Squamous Cell Carcinoma
        • Others
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Therapy Type:
        • Chemotherapy
          • Docetaxel
          • Irinotecan
          • Trifluridine and Tipiracil
          • Carboplatin and Paclitaxel
          • Cisplatin and 5-fluorouracil
          • Cisplatin with Capecitabine
        • Targeted Drug Therapy
          • Trastuzumab
          • Ramucirumab
        • Immunotherapy
          • Pembrolizumab          
      • By Disease Indication:
        • Adenocarcinomas
        • Gastrointestinal Stromal Tumors
        • Carcinoid Tumors
        • Squamous Cell Carcinoma
        • Others
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Therapy Type:
        • Chemotherapy
          • Docetaxel
          • Irinotecan
          • Trifluridine and Tipiracil
          • Carboplatin and Paclitaxel
          • Cisplatin and 5-fluorouracil
          • Cisplatin with Capecitabine
        • Targeted Drug Therapy
          • Trastuzumab
          • Ramucirumab
        • Immunotherapy
          • Pembrolizumab          
      • By Disease Indication:
        • Adenocarcinomas
        • Gastrointestinal Stromal Tumors
        • Carcinoid Tumors
        • Squamous Cell Carcinoma
        • Others
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Therapy Type:
        • Chemotherapy
          • Docetaxel
          • Irinotecan
          • Trifluridine and Tipiracil
          • Carboplatin and Paclitaxel
          • Cisplatin and 5-fluorouracil
          • Cisplatin with Capecitabine
        • Targeted Drug Therapy
          • Trastuzumab
          • Ramucirumab
        • Immunotherapy
          • Pembrolizumab          
      • By Disease Indication:
        • Adenocarcinomas
        • Gastrointestinal Stromal Tumors
        • Carcinoid Tumors
        • Squamous Cell Carcinoma
        • Others
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Therapy Type:
        • Chemotherapy
          • Docetaxel
          • Irinotecan
          • Trifluridine and Tipiracil
          • Carboplatin and Paclitaxel
          • Cisplatin and 5-fluorouracil
          • Cisplatin with Capecitabine
        • Targeted Drug Therapy
          • Trastuzumab
          • Ramucirumab
        • Immunotherapy
          • Pembrolizumab          
      • By Disease Indication:
        • Adenocarcinomas
        • Gastrointestinal Stromal Tumors
        • Carcinoid Tumors
        • Squamous Cell Carcinoma
        • Others
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Therapy Type:
        • Chemotherapy
          • Docetaxel
          • Irinotecan
          • Trifluridine and Tipiracil
          • Carboplatin and Paclitaxel
          • Cisplatin and 5-fluorouracil
          • Cisplatin with Capecitabine
        • Targeted Drug Therapy
          • Trastuzumab
          • Ramucirumab
        • Immunotherapy
          • Pembrolizumab          
      • By Disease Indication:
        • Adenocarcinomas
        • Gastrointestinal Stromal Tumors
        • Carcinoid Tumors
        • Squamous Cell Carcinoma
        • Others
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
  • Company Profiles
    • Amgen Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Eli Lilly and Company
    • Hoffmann-La Roche
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb
    • GlaxoSmithKline Plc.
    • Novartis AG
    • Johnson & Johnson
    • Gilead Sciences
    • Genentech Inc.
    • Sanofi-Aventis
    • Merck & Co.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Therapy Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Landscape
    • Product Recall
    • Epidemiology Analysis
    • Technology Overview
    • PEST Analysis
    • Porter’s Five Forces model
  4. Global Esophageal Cancer Drugs Market, By Therapy Type,  2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
        • Docetaxel
        • Irinotecan
        • Trifluridine and tipiracil
        • Carboplatin and paclitaxel
        • Cisplatin and 5-fluorouracil
        • Cisplatin with capecitabine
    • Targeted Drug Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
        • Trastuzumab
        • Ramucirumab
    • Immunotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
        • Pembrolizumab
  5. Global Esophageal Cancer Drugs Market, By Disease Indication, 2019 – 2027, (US$ Million)
    •  Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Adenocarcinomas
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Gastrointestinal Stromal Tumors
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Carcinoid Tumors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Squamous Cell Carcinoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
  6. Global Esophageal Cancer Drugs Market, By Distribution Channel 2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Retail Pharmacy
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Online Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
  7. Global Esophageal Cancer Drugs Market, By Region, 2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Therapy Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Therapy Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Therapy Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Therapy Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Therapy Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2019 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Therapy Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • Amgen Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Hoffmann-La Roche
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bristol-Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Gilead Sciences
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Genentech Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi-Aventis
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck & Co.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 38 market data tables and 27 figures on "Esophageal Cancer Drugs Market” - Global forecast to 2026”

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.